Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.
about
A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virusMolecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza virusesIsolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C virusesModified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesTwo years after pandemic influenza A/2009/H1N1: what have we learned?Cutaneous immunization: an evolving paradigm in influenza vaccinesSerum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.Fatal outcome of pandemic H1N1 2009 influenza virus infection is associated with immunopathology and impaired lung repair, not enhanced viral burden, in pregnant miceRevisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice.Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine.The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferretsSevere pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responsesEffect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus.Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.Serologic assays for influenza surveillance, diagnosis and vaccine evaluation.Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth.Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel.Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protectionContribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.Immunological assessment of influenza vaccines and immune correlates of protection.Kinetics, longevity and cross-reactivity of anti-neuraminidase antibody after natural infection with influenza A viruses.The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals.Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase SubtypeNeuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness
P2860
Q27316330-863B81D0-648A-4F16-8EAC-7A201918EC4FQ28387782-10D523DA-E6F8-4032-8665-4D9292702A5AQ28486082-205F8880-6AC2-432A-967F-091EE34256B0Q30209342-43A9BDCA-4775-47CD-91E3-E1B05124810DQ30224656-CFB226A5-E9C0-4A6E-A43B-8D06FA4A2727Q30358895-D99E1B6F-6B32-42A5-9CB7-455E0F225CA0Q30373917-0EE0FE49-BED3-4E3E-932E-7CEE8A59973BQ30406363-449F691C-F572-432A-8285-47578E681906Q30407834-CA733CCB-1E65-46F2-9ABD-DEABDD613895Q30410129-E71F9890-FB4D-4BB4-B4F2-07058232CC94Q30412266-4679E4DA-10D1-4067-A321-D0091A7C57CCQ30413023-9E9C0284-9507-47F9-B37A-72DCDBDD75CAQ30413489-CF1230D9-AC72-49E7-8B2F-1CCB66761E3BQ30417675-A71819A3-7277-465D-A54F-8496E773CD54Q30429058-CFE12A85-0EA5-440C-A147-C5D0F7C69AB6Q33820732-86BA3656-2014-4660-B47B-FD3B89F33F89Q34194336-23D5CBBF-EE2B-4705-A598-2E3138AF47F9Q35192297-70E7FF89-87E8-418D-8061-082F5073E9A8Q35408014-E564BE59-E7F3-4467-AB34-02252EE138D7Q35885039-5BB1AA86-0F33-48F0-8E27-B339AEA841A9Q36075789-83D28816-6E16-4960-AA13-C7D9FAA77A7CQ36462309-E98B503C-20A0-4806-A997-AE4984005031Q38105339-DDE1E6C7-F23A-46D1-A05E-1FF93A5A09DCQ41918783-4E87089D-47A5-4E5E-B9D3-295CC17C01A3Q47576940-83CBBBC0-70F9-42FB-8EA6-132188254966Q54217203-16FE8218-C7C9-4040-A0CE-D9C62890C670Q57093905-EF37819C-4E5D-4B70-BCD5-B60CE6F4BA99Q57094018-6DD2E64A-8E39-44C4-9CD4-C7A8E138F883
P2860
Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Inactivated seasonal influenza ...... us in an age-dependent manner.
@ast
Inactivated seasonal influenza ...... us in an age-dependent manner.
@en
type
label
Inactivated seasonal influenza ...... us in an age-dependent manner.
@ast
Inactivated seasonal influenza ...... us in an age-dependent manner.
@en
prefLabel
Inactivated seasonal influenza ...... us in an age-dependent manner.
@ast
Inactivated seasonal influenza ...... us in an age-dependent manner.
@en
P2093
P2860
P50
P356
P1476
Inactivated seasonal influenza ...... rus in an age-dependent manner
@en
P2093
Ali H Ellebedy
Ashley D Webb
Glendie Marcelin
Hilliary M Bland
Janet E McElhaney
Jennifer L DeBeauchamp
Yolanda S Griffin
P2860
P304
P356
10.1086/657084
P407
P577
2010-10-27T00:00:00Z